STOCK TITAN

Kenvue Inc. - KVUE STOCK NEWS

Welcome to our dedicated page for Kenvue news (Ticker: KVUE), a resource for investors and traders seeking the latest updates and insights on Kenvue stock.

Kenvue Inc. (NYSE: KVUE) is recognized as the world's largest pure-play consumer health company, boasting an impressive annual revenue of $15 billion. Established as an independent entity in May 2023 after its spin-off from Johnson & Johnson's consumer segment, Kenvue has rapidly distinguished itself in the market. The company's diverse portfolio spans across several key sectors within the consumer health industry, including cough, cold, and allergy care, pain management, face and body care, oral care, and women's health.

Some of the most iconic brands under Kenvue's umbrella include Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. These brands hold significant market positions globally, attributed to their strong brand equity and consumer trust. Despite operating in a highly fragmented and competitive industry, Kenvue's commitment to quality and innovation has kept it ahead of the curve.

Recently, Kenvue has made strides in its environmental, social, and governance (ESG) initiatives. In May 2024, the Science Based Targets initiative (SBTi) validated Kenvue's near-term greenhouse gas (GHG) emissions reduction targets, aligning with the goal to limit global temperature rise to 1.5°C. This validation underscores Kenvue's dedication to sustainability and its mission to advance the well-being of both people and the planet through its Healthy Lives Mission.

Financially, Kenvue maintains a robust position with a clear focus on expanding its product lines and market reach. The company continues to invest in research and development to enhance its product offerings. Strategic partnerships and collaborations are also central to Kenvue's growth strategy, further solidifying its presence in the consumer health sector.

For the latest updates and information on Kenvue's performance, current projects, and recent achievements, investors and stakeholders are encouraged to visit the company's official website and review its filings with the Securities and Exchange Commission.

Rhea-AI Summary
Kenvue Inc. (NYSE: KVUE) reported a 3.3% increase in net sales to $15.4 billion for FY’23, with organic growth of 5.0%. However, Q4’23 saw a 2.7% decrease in net sales to $3.7 billion, with organic growth of (2.4)%. The company's full-year and fourth quarter financial results, including gross profit margin, adjusted operating income margin, interest expense, net, and taxes, were also disclosed. Kenvue expects 2024 net sales growth of 1.0% to 3.0% with organic growth in the range of 2.0% to 4.0%. Adjusted operating income margin is projected to be slightly below 2023, with adjusted diluted earnings per share expected to be in the range of $1.10 - $1.20.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.8%
Tags
-
News
Rhea-AI Summary
Kenvue Inc. (NYSE: KVUE) has declared a dividend of $0.20 per share on its common stock, payable in the first quarter of 2024. The dividend will be paid on February 28, 2024, to shareholders of record as of February 14, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.57%
Tags
dividends
-
Rhea-AI Summary
Kenvue Inc. (NYSE: KVUE) will announce its financial results for the fourth quarter and full year ending December 31, 2023, before market open on February 8, 2024. The company, the world’s largest pure-play consumer health company by revenue, will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.15%
Tags
Rhea-AI Summary
Kenvue Inc. (KVUE) will participate in Morgan Stanley's Global Consumer & Retail Conference. CEO Thibaut Mongon and CFO Paul Ruh will have a fireside chat on December 6, 2023. The webcast will be available at https://investors.kenvue.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Kenvue Inc. reports a 3.3% increase in net sales and 3.6% organic growth for the fiscal third quarter. Gross profit margin and adjusted operating income margin also improved. The company expects a headwind from foreign exchange and a softer start to the cold, cough, and flu season, impacting its sales outlook. Kenvue paid a third-quarter cash dividend of $0.20 per share and authorized a share repurchase program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.27%
Tags
-
Rhea-AI Summary
Kenvue Inc. to announce Q3 financial results on October 26, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
Rhea-AI Summary
Kenvue Inc. separates from Johnson & Johnson, becoming a fully independent company. Johnson & Johnson now owns 9.5% of Kenvue common stock. Kenvue expects to join the S&P 500 index on August 25, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
none
-
Rhea-AI Summary
Johnson & Johnson announced the final results of its exchange offer with Kenvue Inc. Johnson & Johnson accepted 190,955,436 shares of its common stock in exchange for 1,533,830,450 shares of Kenvue common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
none
-
Rhea-AI Summary
Johnson & Johnson's exchange offer for Kenvue common stock was oversubscribed, with approximately 23.8% of tendered shares expected to be exchanged. Shareholders with fewer than 100 shares will not be subject to proration. Johnson & Johnson will retain approximately 9.5% of Kenvue common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.98%
Tags
none
Rhea-AI Summary
Johnson & Johnson (NYSE: JNJ) has announced the final exchange ratio for its split-off exchange offer to shareholders. For each share of Johnson & Johnson common stock tendered and accepted, the company will deliver 8.0324 shares of Kenvue Inc. common stock. Johnson & Johnson expects to accept approximately 190,955,436 shares if the offer is fully subscribed. The exchange offer is scheduled to expire on August 18, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
none

FAQ

What is the current stock price of Kenvue (KVUE)?

The current stock price of Kenvue (KVUE) is $23.04 as of November 4, 2024.

What is the market cap of Kenvue (KVUE)?

The market cap of Kenvue (KVUE) is approximately 44.2B.

What is Kenvue Inc.?

Kenvue Inc. is the world's largest pure-play consumer health company, generating $15 billion in annual revenue.

When did Kenvue go public?

Kenvue went public in May 2023 after spinning off from Johnson & Johnson's consumer segment.

What are some of Kenvue's well-known brands?

Kenvue's portfolio includes brands like Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena.

What sectors does Kenvue operate in?

Kenvue operates in sectors like cough, cold and allergy care, pain management, face and body care, oral care, and women's health.

What recent achievements has Kenvue made?

Kenvue's near-term GHG emissions reduction targets were recently validated by the Science Based Targets initiative (SBTi).

What is Kenvue's Healthy Lives Mission?

Kenvue's Healthy Lives Mission aims to advance the well-being of both people and the planet by setting and achieving ambitious sustainability goals.

How does Kenvue approach ESG initiatives?

Kenvue is committed to environmental, social, and governance (ESG) initiatives, focusing on reducing its greenhouse gas emissions and promoting sustainability.

What is the financial condition of Kenvue?

Kenvue maintains a strong financial position, with strategic investments in research, development, and collaborations enhancing its market presence.

How can I find more information about Kenvue's financial performance?

For detailed financial information, visit Kenvue's official website and review its SEC filings.

Who can I contact for investor relations at Kenvue?

For investor relations inquiries, contact Tina Romani at Kenvue_IR@kenvue.com.

Kenvue Inc.

NYSE:KVUE

KVUE Rankings

KVUE Stock Data

44.25B
1.92B
0.02%
102.32%
1.62%
Household & Personal Products
Perfumes, Cosmetics & Other Toilet Preparations
Link
United States of America
SKILLMAN